Skip to main content

Together we are beating cancer

Donate now

Cancer News

Latest News

Showing 12 out of 6197 results
This entry is part 1 of 3 in the series CRUK Global
%postcontent%

This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers. This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.

by Phil Prime | Podcast | 6 September 2022

6 September 2022

This entry is part 6 of 9 in the series Cancer Research Matters - series 1
%postcontent%
An electron microscope image of white blood cells

In 1930, it was discovered that children with Down syndrome are at a greater risk of developing certain types of leukaemia, but much of our understanding of this link remains a mystery. In 1930, it was discovered that children with Down syndrome are at a greater risk of developing certain types of leukaemia, but much of our understanding of this link remains a mystery.

by Lilly Matson | Analysis, Personal stories | 1 September 2022

1 September 2022

This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed. This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed.

by Phil Prime | Podcast | 25 August 2022

25 August 2022

This entry is part 5 of 9 in the series Cancer Research Matters - series 1
%postcontent%
A illustration of T cells, a type of immune cell attacking cancer

If we’re to reduce the risk of bowel cancer in people with IBD, we’re going to have to find a more effective treatment. And we may have done just that.  If we’re to reduce the risk of bowel cancer in people with IBD, we’re going to have to find a more effective treatment. And we may have done just that. 

by Jacob Smith | Analysis | 23 August 2022

23 August 2022

We catch up with Dr Alexis Webb and find out about the upcoming Early Detection of Cancer Conference, the importance of collaboration and why these are exciting times for the field... We catch up with Dr Alexis Webb and find out about the upcoming Early Detection of Cancer Conference, the importance of collaboration and why these are exciting times for the field...

by Phil Prime | Interview | 18 August 2022

18 August 2022

A photograph of two people setting up a CRUK fundraising event

We support lifesaving cancer research through the work of over 4,000 scientists, doctors and nurses. But none of what we do would be possible without those who support us.  We support lifesaving cancer research through the work of over 4,000 scientists, doctors and nurses. But none of what we do would be possible without those who support us. 

by Lilly Matson | Personal stories | 17 August 2022

17 August 2022

CRISPR-Cas9 is a world-renowned genome editing tool, but much of the hype has been focused on direct clinical applications. However, there is clear potential for utilising the system in functional genomic screens to develop new cancer medicines... CRISPR-Cas9 is a world-renowned genome editing tool, but much of the hype has been focused on direct clinical applications. However, there is clear potential for utilising the system in functional genomic screens to develop new cancer medicines...

by Cancer Research UK | In depth | 16 August 2022

16 August 2022